On 28 April, Annovis Bio announced the publication of new Phase II/III clinical trial findings for its investigational oral therapy buntanetap in the peer-reviewed journal Nature NPJ Dementia.
The randomised, double-blinded and placebo-controlled study evaluated three doses of buntanetap (7.5 mg, 15 mg and 30 mg) over 12 weeks in 351 people with mild to moderate Alzheimer’s disease (AD). Results showed that the treatment was safe and well tolerated across all disease stages and dose levels, including in ApoE4 carriers, a population considered at higher genetic risk for AD. The analyses also demonstrated statistically significant, dose-dependent improvements in cognition, measured using ADAS-Cog11, in pTau217 biomarker-positive participants with early AD.
The findings support the company’s ongoing pivotal Phase III trial in early AD, which has enrolled approximately 80% of participants to date. The study is designed to assess both symptomatic and potential disease-modifying effects of buntanetap over 6 and 18 months, respectively.
https://doi.org/10.1038/s44400-026-00073-z
